<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789137</url>
  </required_header>
  <id_info>
    <org_study_id>A6181218</org_study_id>
    <secondary_id>TROYA</secondary_id>
    <nct_id>NCT02789137</nct_id>
  </id_info>
  <brief_title>Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment</brief_title>
  <acronym>TROYA</acronym>
  <official_title>PROSPECTIVE, MULTICENTRE, OBSERVATIONAL STUDY ON FATIGUE- AND HAND-FOOT SYNDROME-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING A TYROSINE KINASE INHIBITOR AS FIRST-LINE TREATMENT (TROYA STUDY).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to know about the quality of life of patients with metastatic
      renal cell carcinoma who are being treated with sunitinib, pazopanib or sorafenib, and who
      suffer from fatigue and hand-foot syndrome, with personal inter-variability, and to explore
      measures that can be taken in terms of both everyday lifestyle and treatment to mitigate or
      cure such side effects that affect patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentre, observational study in patients with metastatic renal cell
      carcinoma (mRCC) receiving a tyrosine kinase inhibitor as first-line treatment according to
      routine clinical practice, designed to evaluate the incidence of fatigue and hand-foot
      syndrome in order to determine how these affect the baseline characteristics of the patient
      and his/her disease (age, gender, baseline status, tumour histology, etc.) and the patient's
      lifestyle as such side effects develop.

      An exploratory analysis will be performed of measures that clinicians may adopt to improve
      patients' quality of life with regards to daytime naps, medication administration time,
      off-treatment periods, dose reductions and treatment breaks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 22, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Fatigue-related quality of life with validated 13-item FACIT-Fatigue scale for patients with metastatic renal cancer in Spanish</measure>
    <time_frame>9 months</time_frame>
    <description>Fatigue-related quality of life of patients receiving a tyrosine kinase inhibitor evaluated using the validated 13-item FACIT-Fatigue scale for patients with metastatic renal cancer in Spanish</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life in patients with palmar-plantar erythrodysaesthesia according to version 4 of the CTCAE</measure>
    <time_frame>9 months</time_frame>
    <description>Quality of life in patients with palmar-plantar erythrodysaesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse effects according to version 4 of the CTCAE</measure>
    <time_frame>9 months</time_frame>
    <description>To assess the following adverse effects according to version 4 of the CTCAE (Common Terminology Criteria for Adverse Events): any grade of fatigue and hand-foot syndrome (HFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>9 months</time_frame>
    <description>Time to Treatment Failure (TTF), defined as the time from the start of treatment with a tyrosine kinase inhibitor to tumour progression, treatment discontinuation for any reason or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) (median)</measure>
    <time_frame>9 months</time_frame>
    <description>Progression-Free Survival (PFS) (median): time from the start of treatment with a tyrosine kinase inhibitor to tumour progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate according to RECIST version 1.1.</measure>
    <time_frame>9 months</time_frame>
    <description>Objective Response Rate according to RECIST version 1.1.</description>
  </secondary_outcome>
  <enrollment type="Actual">111</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        A population of 100 patients aged 18 years or over and diagnosed with metastatic renal cell
        carcinoma who are to start first-line treatment with a tyrosine kinase inhibitor according
        to routine clinical practice is to be studied
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years old and diagnosed with metastatic RCC who, in the investigator's
             opinion, are candidates for starting first-line treatment with a tyrosine kinase
             inhibitor according to routine clinical practice.

          -  Patients who have no contraindications to the treatment.

          -  Baseline ECOG ≤ 2.

          -  Patients who are able to give informed consent on their own without the need for a
             legal representative.

          -  Committed patients who are able to complete the quality of life questionnaires and
             patient diary on their own without the need for a legal representative.

        Exclusion Criteria:

          -  Patients who are not candidates for first-line treatment with a tyrosine kinase
             inhibitor.

          -  Patients who are receiving the treatment as second-line or subsequent therapy.

          -  Untreated hypothyroidism.

          -  Untreated severe anaemia.

          -  Pregnancy or breast-feeding.

          -  Myocardial infarction or cerebrovascular accidents (CVA) within the last 6 months.

          -  Severe hepatic impairment.

          -  Concomitant use of potent inhibitors or inducers that interact with hepatic cytochrome
             CYP3A4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide de Ferrol</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Asil de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakano</name>
      <address>
        <city>Usansolo</city>
        <state>Bizkaia</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario la Mancha Centro</name>
      <address>
        <city>Alcazar de San Juan</city>
        <state>Ciudad REAL</state>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Reus / Servicio de Oncología Médica</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall de Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Reina Sofía de Cordoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Girona (Hospital Dr.Josep Trueta)</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de León</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa / Servicio de Oncología Médica</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Ourense. Hospital Santa María Nai</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau i Santa Tecla</name>
      <address>
        <city>Tarragona</city>
        <zip>43003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Clínico Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A6181218</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Hand-Foot Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

